What Is Larazotide?

First, larazotide, usually studied as larazotide acetate and historically called AT-1001, is a synthetic linear octapeptide developed as an oral intestinal tight-junction regulator.

Next, it was derived from research involving zonula occludens toxin (Zot), an intestinal-permeability-modifying protein produced by Vibrio cholerae. Larazotide was designed from a biologically active Zot-related peptide region but has effects opposite to barrier-opening Zot fragments: it is intended to reduce inappropriate tight-junction disassembly and paracellular permeability.

Moreover, researchers have studied the compound most extensively as an adjunct to a gluten-free diet in adults with celiac disease who continue to experience symptoms or undergo controlled gluten challenge.

🧬 Molecular Structure

First, larazotide is a short, linear peptide containing eight amino acids. It has a free N-terminus and a free C-terminal carboxyl group. The investigational drug material is commonly described as the acetate form.

🧪 Amino-Acid Sequence

H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH

One-letter notation: GGVLVQPG

⚛️ Molecular Weight and 🧫 Formula

Therefore, molecular formula and mass can differ depending on whether a source reports the neutral peptide, acetate-associated material, hydrate, or another analytical form. A COA must identify the exact basis used for assay calculations.

📅 Development Timeline

1990s: Zonulin and Zot signaling research develops

First, investigators studying cholera toxin biology identified Zot-related effects on intestinal epithelial tight junctions and paracellular permeability.

Early 2000s: AT-1001 developed

Next, developers created a synthetic octapeptide based on Zot-related research to regulate rather than open epithelial tight junctions.

2006–2010: Early human celiac studies

Then, Phase 1 and early Phase 2 studies evaluated oral safety, intestinal permeability, gluten-challenge responses, antibodies, cytokines, and symptoms.

2012: Cellular tight-junction work published

Moreover, preclinical research reported that larazotide inhibited gliadin- and Zot-fragment-induced rearrangement of ZO-1 and actin and helped preserve transepithelial resistance.

2013–2015: Gluten-challenge and persistent-symptom trials

In addition, randomized studies reported mixed permeability and biomarker results, with some reduction in gastrointestinal symptoms and gluten-triggered immune responses.

2019: CedLara Phase 3 study begins

Meanwhile, the multicenter Phase 3 trial evaluated larazotide for persistent symptoms in adults with celiac disease following a gluten-free diet.

2022: Phase 3 study discontinued

Importantly, the sponsor discontinued CedLara after interim statistical review indicated that a substantial increase in enrollment would be necessary to obtain a scientifically meaningful result.

2025–2026: Mechanistic research continues

Finally, cellular and animal studies continue to examine barrier protection and possible applications, but larazotide remains unapproved and no successful confirmatory Phase 3 program has established clinical use.

📖 Research History

Importantly, developers created larazotide around the concept that reducing paracellular passage of gluten-derived peptides might reduce downstream immune activation and symptoms in celiac disease.

However, clinical development produced an unusual dose-response pattern. In one major Phase 2b study, the lowest tested dose produced the clearest symptom improvement, while higher doses did not consistently outperform placebo. This may reflect local luminal pharmacology, peptide aggregation, receptor dynamics, formulation effects, or trial variability.

Moreover, most trials did not establish consistent improvement across all permeability, serologic, inflammatory, histologic, and symptom endpoints. Symptom findings were more encouraging than objective mucosal-healing evidence.

Intestinal Barrier and Tight-Junction Biology

First, the intestinal epithelium separates luminal contents from underlying immune and vascular compartments. Molecules can cross through cells by transcellular transport or between cells through the paracellular pathway.

Major tight-junction components

• Claudins: First, Form selective paracellular pores and barriers.
• Occludin: Next, Participates in junction regulation and barrier signaling.
• ZO-1, ZO-2, and ZO-3: Also, Scaffold proteins linking membrane proteins to actin.
• Junctional adhesion molecules: Moreover, Support cell-cell contact and signaling.
• Actomyosin cytoskeleton: In addition, Generates tension that can open or tighten the junctional complex.

Myosin light-chain kinase

Moreover, inflammatory and microbial signals can activate myosin light-chain kinase, increasing actomyosin contraction and pulling junctional structures apart. Larazotide has been associated with inhibition of this pathway in experimental systems.

Zonulin terminology

However, zonulin is commonly described as an endogenous regulator of intestinal permeability and has been linked to pre-haptoglobin 2. However, commercial “zonulin” assays and the broader interpretation of circulating zonulin biomarkers are scientifically controversial. Larazotide mechanism claims should therefore not depend solely on nonspecific zonulin blood-test results.

🧠 Proposed Mechanism of Action

First, researchers describe larazotide as a locally acting tight-junction regulator. Its complete molecular target has not been definitively established.

1. Luminal gluten exposure

Next, in celiac disease, incompletely digested gluten peptides interact with the intestinal epithelium and immune system.

2. Barrier-regulatory signaling

Moreover, gliadin and other signals can alter actin organization, tight-junction proteins, transepithelial resistance, and paracellular transport.

3. Larazotide acts locally

In addition, developers intended oral larazotide to act at the luminal epithelial surface rather than through high systemic exposure.

4. Junctional protein preservation

Likewise, experimental studies report reduced redistribution of ZO-1, occludin, and actin and improved epithelial electrical resistance.

5. Possible MLCK inhibition

Meanwhile, recent mechanistic reviews and cellular work associate larazotide with reduced myosin light-chain kinase activity and lower actomyosin tension.

6. Indirect immune effect

Finally, by reducing passage of immunogenic material, larazotide could theoretically reduce downstream immune stimulation without acting as a broad systemic immunosuppressant.

🎯 Target and Pathway Profile

Human Clinical Evidence

Early safety and gluten-challenge studies

First, initial trials generally found larazotide to be well tolerated and suggested possible protection against gluten-induced symptoms, antibody changes, or permeability responses. Objective permeability findings were inconsistent.

Phase 2b persistent-symptom trial

Next, a randomized study in adults with persistent celiac symptoms despite a gluten-free diet found that 0.5 mg three times daily improved certain symptom outcomes. Higher doses did not demonstrate the same consistent benefit, and histologic healing was not established as a primary clinical success.

Gluten-free diet remains essential

Importantly, researchers studied larazotide as an adjunct, not as permission to consume gluten. Even a successful barrier therapy would not necessarily block every transcellular, paracellular, innate, or adaptive immune pathway involved in celiac disease.

Phase 3 CedLara outcome

However, the Phase 3 study was designed to evaluate symptom relief in adults with celiac disease who remained symptomatic while following a gluten-free diet. It was discontinued after interim analysis because obtaining a meaningful result was projected to require substantially more participants. The trial therefore did not provide confirmatory Phase 3 evidence supporting approval.

What the evidence supports

• First, Human oral exposure and a generally placebo-like safety profile in earlier trials
• Next, Possible symptom reduction in selected celiac populations
• Also, Biologically plausible local barrier effects

What the evidence does not establish

• First, FDA-approved treatment of celiac disease
• Next, Replacement of a gluten-free diet
• Also, Consistent mucosal healing
• Moreover, Broad treatment of nonspecific “leaky gut”
• In addition, Clinical efficacy in inflammatory bowel disease, metabolic disease, or systemic autoimmune disease

Other Research Areas

Inflammatory bowel disease

First, barrier dysfunction is relevant to Crohn disease and ulcerative colitis, but clinical evidence has not established larazotide as an approved or adequately proven IBD treatment.

Type 1 diabetes and autoimmunity

Moreover, increased permeability is studied in autoimmune disease models. These associations do not demonstrate that tightening junctions reverses established autoimmunity.

Infectious and toxin-mediated injury

In addition, preclinical studies have examined protection from bacterial toxins, inflammatory cytokines, and epithelial injury.

Respiratory viral research

Likewise, larazotide derivatives have been explored computationally or experimentally for antiviral applications. These are separate from the original celiac clinical program and remain preclinical.

Pediatric and multisystem inflammatory research

Finally, small exploratory studies have examined zonulin-related barrier pathways in pediatric inflammatory syndromes. These findings are preliminary and cannot establish routine treatment.

Safety and Regulatory Considerations

Clinical-trial tolerability

First, earlier celiac trials generally reported adverse-event frequencies similar to placebo. Reported events were commonly mild gastrointestinal symptoms, headache, respiratory symptoms, or nonspecific complaints.

Local exposure does not eliminate risk

Moreover, low systemic absorption may reduce systemic toxicity, but product identity, oral formulation, microbiological quality, impurities, and interactions remain important.

Long-term uncertainty

Importantly, there is no approved long-term treatment regimen, commercial prescribing information, or established postmarketing safety database.

Self-treatment risk

In addition, persistent gastrointestinal symptoms can result from ongoing gluten exposure, refractory celiac disease, microscopic colitis, pancreatic insufficiency, infection, inflammatory bowel disease, malignancy, or other conditions requiring diagnosis.

Regulatory status

Finally, larazotide acetate is not FDA approved. Fast Track designation and completion of earlier trials do not equal approval or proof of effectiveness.

🧪 Laboratory Testing Methods

📄 How to Interpret a Larazotide COA

1. Confirm the full sequence

First, the expected sequence is H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH.

2. Identify acetate and material basis

Next, the report should state whether it covers neutral larazotide, larazotide acetate, a hydrate, or a formulated oral product.

3. Separate identity, purity, and content

• Identity First, confirms the octapeptide.
• Purity Next, estimates relative chromatographic composition.
• Assay Also, measures actual peptide content.

4. Review deamidation and truncation

Moreover, glutamine deamidation, peptide-bond hydrolysis, deletion sequences, and terminal modifications can alter quality.

5. Check oral-product microbiology

In addition, oral research material should have appropriate microbial-limit, water-activity, stability, and contaminant testing. Injectable sterility claims are irrelevant to the route studied clinically unless an injectable product is separately being developed.

6. Do not infer efficacy from purity

However, a 99% HPLC result does not prove oral stability, luminal release, epithelial exposure, tight-junction activity, or clinical symptom improvement.

📊 Larazotide vs KPV vs BPC-157 vs LL-37

Mechanisms and Evidence Differences

Larazotide vs Gluten-Degrading Enzymes vs Immune Therapies

Therapeutic-Strategy Differences

🔗 Related Compounds and Pathways

• Zonula occludens toxin: First, Bacterial protein that inspired larazotide development.
• AT-1002: Next, Zot-derived barrier-opening peptide used in mechanistic research.
• Zonulin/pre-haptoglobin 2: Also, Endogenous permeability-related signaling framework associated with celiac research.
• Myosin light-chain kinase: Moreover, Regulator of actomyosin tension and paracellular permeability.
• ZO-1 and occludin: In addition, Key tight-junction proteins examined in larazotide studies.
• Gliadin: Likewise, Gluten protein fraction involved in celiac immune activation.

🖼️ Original Diagram Specifications

Diagram 1: Larazotide sequence map

By contrast, Show the eight residues GGVLVQPG with a free N-terminus, free C-terminal carboxyl group, and acetate association.

Diagram 2: Healthy vs disrupted tight junction

Also, Compare organized claudin, occludin, ZO-1, and actin with gliadin- or inflammatory-signal-induced junctional disruption.

Diagram 3: Proposed larazotide pathway

Consequently, Show larazotide at the luminal epithelial surface reducing MLCK-related actomyosin tension and preserving ZO-1 and occludin localization.

Diagram 4: Celiac disease pathway

However, Show gluten digestion, epithelial passage, tissue transglutaminase deamidation, HLA-DQ2/DQ8 presentation, T-cell activation, and villous injury. Mark larazotide only at the barrier step.

Diagram 5: Clinical evidence timeline

Therefore, Show Phase 1, gluten-challenge studies, Phase 2b symptom findings, Phase 3 initiation, and 2022 discontinuation.

Diagram 6: COA workflow

For example, Show sequence confirmation, HPLC purity, LC-MS identity, acetate, assay, water, residual solvents, microbial limits, stability, and cell-barrier activity.

❓ Frequently Asked Questions

Is larazotide a peptide?

Meanwhile, Yes. It is a synthetic linear octapeptide with the sequence GGVLVQPG.

Is larazotide FDA approved?

Likewise, No. It remains investigational.

Did larazotide complete a successful Phase 3 trial?

In addition, No. The CedLara Phase 3 trial was discontinued after interim analysis indicated that substantially more enrollment would be needed for a meaningful result.

What was larazotide studied for?

Moreover, researchers studied it mainly as an adjunct for persistent symptoms or controlled gluten exposure in adults with celiac disease.

Does it cure celiac disease?

By contrast, No. It does not eliminate the autoimmune response or replace a strict gluten-free diet.

Does larazotide treat “leaky gut”?

Also, It has been studied for increased intestinal permeability in defined experimental and celiac settings. Evidence does not support treating all nonspecific “leaky gut” complaints with larazotide.

Is it an anti-inflammatory peptide?

Consequently, Its primary proposed action is barrier regulation. Any reduction in inflammation would be indirect rather than broad immune suppression.

Is it systemically absorbed?

However, development emphasized local gastrointestinal activity and low systemic exposure, although formulation-specific pharmacokinetic data remain necessary.

Why did lower doses sometimes perform better?

Therefore, The reason is not fully established. Possible explanations include local concentration behavior, aggregation, target dynamics, formulation, or trial variability.

Does a high-purity COA prove clinical activity?

For example, No. Chemical purity does not prove oral delivery, epithelial target exposure, tight-junction regulation, or symptom benefit.

Larazotide Scientific Overview: Final Thoughts

In conclusion, larazotide acetate is a scientifically distinctive octapeptide developed to regulate intestinal tight junctions rather than directly suppress immune cells. Its strongest research history is in celiac disease, where early and Phase 2 studies suggested possible symptom benefit and a generally favorable short-term safety profile.

However, the evidence is mixed across permeability, biomarker, histology, and symptom outcomes. The Phase 3 CedLara trial was discontinued and did not establish confirmatory efficacy. Larazotide therefore remains an unapproved investigational compound.

Therefore, its broader relevance to inflammatory bowel disease, autoimmunity, infection, metabolic disease, or general “gut repair” remains exploratory. Accurate product evaluation requires the exact GGVLVQPG sequence, acetate basis, quantitative assay, impurity control, oral-formulation stability, microbiological quality, and—separately—validated functional barrier assays.

📚 References

Clinical, Mechanistic, and Tight-Junction Sources

1. Therefore, National Center for Biotechnology Information. PubChem Compound Summary: Larazotide Acetate.
2. Likewise, ClinicalTrials.gov. Phase 3 study of larazotide acetate for persistent symptoms in celiac disease.
3. For example, Celiac Disease Foundation. Phase 3 larazotide trial discontinued. 2022.
4. Moreover, Taavela J, et al. Upcoming treatments in celiac disease. 2026.
5. In addition, Slifer ZM, Blikslager AT. Larazotide acetate: a pharmacological peptide approach to tight-junction regulation. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2021.
6. However, Slifer ZM, Blikslager AT. Larazotide acetate review. Full-text archive.
7. Therefore, Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012.
8. Likewise, Kim J, et al. Larazotide acetate protects the intestinal mucosal barrier from injury. Biomedicines. 2025.
9. For example, Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet. Gastroenterology. 2015.
10. Moreover, Leffler DA, et al. Phase 2b larazotide trial in persistent celiac symptoms. Gastroenterology. 2015.
11. In addition, Kelly CP, et al. Larazotide acetate in patients with celiac disease undergoing a gluten challenge: randomized placebo-controlled study. Alimentary Pharmacology & Therapeutics. 2013.
12. However, ClinicalTrials.gov. Larazotide acetate in active celiac disease.
13. Therefore, ClinicalTrials.gov. Larazotide acetate during gluten challenge.
14. Likewise, ClinicalTrials.gov. Multiple-dose safety and tolerability study.
15. For example, ClinicalTrials.gov. Safety study of larazotide acetate in celiac disease.
16. Moreover, Khaleghi S, et al. The potential utility of tight-junction regulation in celiac disease: focus on larazotide acetate. Therapeutic Advances in Gastroenterology. 2016.
17. In addition, Fasano A. Zonulin and its regulation of intestinal barrier function. Physiological Reviews. 2011.
18. However, Fasano A. Intestinal permeability and its regulation by zonulin. Clinical Gastroenterology and Hepatology. 2012.

Barrier Biology, Analytical, and Quality Sources

19. Therefore, Tajik N, et al. Targeting zonulin and intestinal epithelial barrier function. Nature Communications. 2020.
20. Likewise, Fasano A, et al. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent signaling. Journal of Clinical Investigation.
21. For example, Tripathi A, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proceedings of the National Academy of Sciences. 2009.
22. Moreover, Scheffler L, et al. Widely used commercial ELISA does not detect precursor of haptoglobin2 but recognizes complement C3. Frontiers in Endocrinology. 2018.
23. In addition, Ajamian M, et al. Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems. PLoS One. 2019.
24. However, Turner JR. Intestinal mucosal barrier function in health and disease. Nature Reviews Immunology. 2009.
25. Therefore, Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nature Reviews Gastroenterology & Hepatology. 2017.
26. Likewise, Shen L, Turner JR. Role of epithelial cells in initiation and propagation of intestinal inflammation. Gastroenterology.
27. For example, Clayburgh DR, et al. Epithelial myosin light-chain kinase-dependent barrier dysfunction mediates T-cell activation-induced diarrhea. Journal of Clinical Investigation.
28. Moreover, Di Micco S, et al. Peptide derivatives of the zonulin inhibitor larazotide. International Journal of Molecular Sciences. 2021.
29. In addition, International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
30. However, United States Pharmacopeia. General Chapter <621>, Chromatography.
31. Therefore, United States Pharmacopeia. General Chapters <61> and <62>, Microbiological Examination of Nonsterile Products.
32. International Council for Harmonisation. ICH Q3C: Impurities—Guideline for Residual Solvents.
33. International Council for Harmonisation. ICH Q6B: Specifications—Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.
34. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products.

Meanwhile, Sequence, molecular properties, mechanism, clinical-trial history, and current Phase 3 status were reviewed in July 2026. Larazotide acetate remains investigational and unapproved.